You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
minimally invasive heart valve<br />
repair device to treat mitral<br />
regurgitation in India.<br />
This clip device repairs<br />
leaky mitral valves without<br />
open-heart surgery and is<br />
delivered to the heart through<br />
a vein in the leg. The device<br />
clips portions of the leaflets,<br />
or flaps, of the mitral valve<br />
together to reduce the<br />
backflow of blood (known as<br />
mitral regurgitation, or MR),<br />
restoring the heart’s ability to<br />
pump oxygenated blood more<br />
efficiently.<br />
To date, this product<br />
has helped treat more than<br />
100,000 people worldwide<br />
suffering from MR and is<br />
supported by an extensive<br />
body of clinical evidence,<br />
including the results of the<br />
landmark COAPT Trial published<br />
in The New England Journal of<br />
Medicine in September 2018.<br />
In addition, the device’s<br />
safety and efficacy is also<br />
supported by 3 randomized<br />
clinical trials, over 30,000<br />
people enrolled in clinical<br />
studies and 1,000+<br />
publications.<br />
With more than 16 years<br />
of clinical experience,<br />
Abbott’s mitral clip<br />
system is the first and<br />
only transcatheter mitral<br />
valve therapy with proven<br />
safety and survival, and<br />
durability of clinical outcomes,<br />
Abbott said.<br />
Morphues8<br />
full-body<br />
fractional RF<br />
tech gets US<br />
patent<br />
InMode Ltd announced that<br />
the US Patent and Trademark<br />
Office (USPTO) has granted<br />
InMode Patent No. 10.799.285<br />
covering its Morphues8 fullbody<br />
fractional radiofrequency<br />
(RF) technology.<br />
Cease and desist notices<br />
have been recently issued<br />
to multiple North American<br />
companies manufacturing<br />
and marketing products<br />
or platforms infringing<br />
on InMode’s Patent No.<br />
10.799.285.<br />
The company has<br />
developed state-of-the-art<br />
electro-surgical bi-polar<br />
radiofrequency devices<br />
including the Morpheus8<br />
Subdermal Adipose<br />
Remodeling (SARD) device.<br />
“The reciprocating<br />
mechanism in RF fractional<br />
devices is a key feature for<br />
delivering fast and uniform<br />
treatments,” said Dr Michael<br />
Kreindel, InMode chief<br />
technology officer.<br />
Novum IQ<br />
infusion platform<br />
gets Canadian<br />
approval<br />
B<br />
axter Canada announced<br />
Health Canada marketing<br />
authorization of its new Novum<br />
IQ infusion platform.<br />
Novum IQ is Baxter’s<br />
innovation in medication<br />
delivery and management.<br />
The marketing authorization<br />
in Canada includes Novum<br />
IQ large volume (LVP) and<br />
syringe infusion pumps as<br />
well as the company’s Dose IQ<br />
Safety Software, representing<br />
Baxter’s latest developments<br />
for infusion therapy and<br />
medication safety.<br />
Illumina introduces NextSeq 2000 with P3 high-output flow cell<br />
Illumina, Inc has launched the<br />
NextSeq 2000 Sequencing<br />
System with the P3 high-output<br />
flow cell.<br />
The P3 flow cell offers 1.1<br />
billion reads in a single sequencing<br />
run, almost three times more<br />
than previously available on<br />
Illumina’s mid-throughput NextSeq<br />
sequencing portfolio, expanding<br />
the range of applications that run<br />
on the system.<br />
“The advanced yet affordable<br />
P3 flow cell for the NextSeq 2000<br />
gives customers more capacity to<br />
increase the depth and breadth<br />
of their projects and the ability<br />
to stretch their project budgets,<br />
yielding deeper insights,” said<br />
Susan Tousi, chief product officer of<br />
Illumina, in a statement.<br />
<strong>December</strong> <strong>2020</strong> / FUTURE MEDICINE / 71
Change language